Cero Therapeutics Holdings Files 8-K
Ticker: CEROW · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1870404
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: CERO
TL;DR
Cero Therapeutics (CERO) filed an 8-K on 9/5/25, updating on corporate events.
AI Summary
Cero Therapeutics Holdings, Inc. filed an 8-K on September 5, 2025, reporting on other events and financial statements. The company, formerly known as Phoenix Biotech Acquisition Corp. until June 30, 2021, is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing provides an update on Cero Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing providing corporate and financial updates without disclosing significant new risks or material events.
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- PHOENIX BIOTECH ACQUISITION CORP. (company) — Former Company Name
- September 5, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
FAQ
What is the primary business of Cero Therapeutics Holdings, Inc.?
Cero Therapeutics Holdings, Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
When did Cero Therapeutics Holdings, Inc. change its name from Phoenix Biotech Acquisition Corp.?
The company changed its name from Phoenix Biotech Acquisition Corp. on June 30, 2021.
What is the fiscal year end for Cero Therapeutics Holdings, Inc.?
The fiscal year end for Cero Therapeutics Holdings, Inc. is December 31.
What is the business address of Cero Therapeutics Holdings, Inc.?
The business address is 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA 94080.
What is the Commission File Number for Cero Therapeutics Holdings, Inc.?
The Commission File Number is 001-40877.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-05 08:32:30
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CERO Nasdaq Capital Market
Filing Documents
- ea0256155-8k_cero.htm (8-K) — 37KB
- ea025615502ex99-1_cero.htm (EX-99.1) — 10KB
- 0001213900-25-084737.txt ( ) — 258KB
- cero-20250905.xsd (EX-101.SCH) — 4KB
- cero-20250905_def.xml (EX-101.DEF) — 26KB
- cero-20250905_lab.xml (EX-101.LAB) — 36KB
- cero-20250905_pre.xml (EX-101.PRE) — 25KB
- ea0256155-8k_cero_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated September 5, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 5, 2025 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2